DrugPatentWatch Database Preview
Clovis Oncology Inc Company Profile
What is the competitive landscape for CLOVIS ONCOLOGY INC, and what generic alternatives to CLOVIS ONCOLOGY INC drugs are available?
CLOVIS ONCOLOGY INC has one approved drug.
There are ten US patents protecting CLOVIS ONCOLOGY INC drugs.
Summary for Clovis Oncology Inc
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Clovis Oncology Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 9,045,487 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 8,754,072 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 8,071,579 | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 9,861,638 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Clovis Oncology Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2955495 | ➤ Sign Up |
| Japan | 2007516241 | ➤ Sign Up |
| Hong Kong | 1084602 | ➤ Sign Up |
| Norway | 338398 | ➤ Sign Up |
| Eurasian Patent Organization | 004989 | ➤ Sign Up |
| Canada | 2533332 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Clovis Oncology Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015 00012 | Denmark | ➤ Sign Up | PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216 |
| C0022 | France | ➤ Sign Up | PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218 |
| 0150012 00136 | Estonia | ➤ Sign Up | PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014 |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
| 3 50005-2015 | Slovakia | ➤ Sign Up | PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218 |
| 15/016 | Ireland | ➤ Sign Up | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
